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Introduction 
This is our 6th annual literature review on mechanical circulatory support (MCS) 
devices. 
Our previous reports for 2014, 2015, 2016, 2017, 2018 were published as open 
access articles and were well received by the readers (1-5). In this paper, we 
summarize the most interesting and important, from our standpoint, publications 
from 2019. As we have done for the past two years, a section on extracorporeal 
membrane oxygenation (ECMO) is included and primarily addresses new 
developments in veno-arterial ECMO (VA ECMO) use.   
Readers who wish to supplement this review, to argue with the author’s 
statements or to express their opinions are encouraged to do so by sending letters 
to the editor mguglin@iu.edu or posting on our Facebook page at 
https://www.facebook.com/TheVADJournal.   
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Outcomes 
The outcomes for patients on left ventricular assist device (LVAD) support remains 
much the same when compared to 2018. The 2019 annual report from the 
Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) 
confirmed an ongoing shift in the use of LVAD for less acute (profile 3) patients (1). 
One-year survival on continuous flow devices was 83%, and 5-year survival was 
46%. The one-year survival rates for centrifugal-flow and axial-flow devices were 
85% and 84%, respectively. At one year, stroke occurred in 20% of patients on 
centrifugal-flow support and 13% of patients on axial-flow support (p < 0.001); 
gastrointestinal bleeding (GIB) affected 20% and 25% (p < 0.001); and pump-
related infections occurred in 28% and 25% of patients, respectively (p= 0.01). 
Neurologic dysfunction (19% of deaths) and multisystem organ dysfunction (15%) 
were the most common causes of death (1). 
Device Studies 
HeartMate II vs. HeartMate 3 
The final analysis from the Multicenter Study of MagLev Technology in Patients 
Undergoing Mechanical Circulatory Support Therapy with HeartMate® 3 (HM3, 
MOMENTUM 3, Abbott), a randomized trial comparing the HM3 and HeartMate II 
(HMII), was published last year (2). Patients were randomly assigned to receive 
either the centrifugal-flow (HM3) or the axial-flow pump (HMII) irrespective of the 
intended goal of use (bridge to transplantation or destination therapy). At two years 
post-implantation, 76.9% in the HM3 group, as compared with 64.8% in the HMII 
group, remained alive and free of disabling stroke or reoperation to replace or 
remove a malfunctioning device, which was the primary endpoint of the trial 
(relative risk, 0.84; 95% confidence interval [CI], 0.78-0.91; P < 0.001 for 
superiority). Pump replacement at two years, the secondary endpoint, was less 
common in the centrifugal-flow pump group than in the axial-flow pump group 
(2.3% vs. 11.3%; relative risk, 0.21; 95% CI, 0.11-0.38; P < 0.001). The numbers 
of events per patient-year for a stroke of any severity, major bleeding, and 
gastrointestinal hemorrhage were lower in the centrifugal-flow pump group than in 
the axial-flow pump group. There was no significant difference in overall survival 
between the groups (2).   
A substudy of the same trial compared strokes in patients supported with these 
two pumps and found that the HM3 pump was associated with a marked reduction 
in stroke rates compared with the HMII (3). Although there was no short-term 
difference in stroke rate (up to 180 days), stroke incidence in the long-term period 
(181-730 days after LVAD) was 3.3 times lower for the HM3 group (HM3: 0.04 
versus HMII: 0.13 events per patient-year; odds ratio, 0.23; 95% CI, 0.08-0.63; P= 
0.01). There was no direct association of blood pressure (BP) or antithrombotic 
regimens with observed stroke rates. A stroke significantly lowered 2-year survival: 
43 ±12% for hemorrhagic stroke, 57±9% for ischemic stroke, 51 ±11% for 
disabling, and 51 ±11% for nondisabling compared with 85 ±2% 2-year survival for 
patients without stroke (3). 
Importantly, as compared to other continuous-flow pumps, the HM3 is likely related 
to lower shear stress due to its fully magnetically levitated rotor. It is well known 
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that von Willebrand factor (vWF) and acquired von Willebrand syndrome play a 
major role in the origin of GIB complications in patients with continuous-flow 
LVADs. In a study published from the Continued Access Protocol of the 
MOMENTUM3 trial, the high molecular weight multimers of vWF were better 
preserved in the HM3 than in HMII supported patients (4). Also, patients with HM3 
devices had a higher level of vWF activity during device support, which may 
reduce the formation of arteriovenous malformations and lead to a lower bleeding 
complication rate (5). 
Fully-Implantable LVAD 
There is a consensus in the MCS world that eliminating the driveline and all 
associated problems would be a breakthrough leading to a dramatically improved 
quality of life for patients with LVADs. A fully implantable LVAD option would 
increase the appeal of this intervention to patients, families, and physicians. Last 
year, two human patients received fully-implantable LVADs (LeviticusCardio, Ltd., 
Petach Tikva, Israel) in Astana, Kazakhstan (6). The system was integrated with 
the Jarvik 2000 (Jarvik Heart, Inc.) and consists of an internal integrated controller 
and battery coupled with an internal thoracic coil ring designed for energy 
harvesting. The required energy was delivered to the device via a coplanar energy 
transfer system comprised of two large rings utilizing a coil-within-the-coil topology. 
This system ensures robust resonance energy transfer while allowing for 
substantial (>6 hours) unholstered circulatory support powered by an implantable 
battery source. The external equipment includes a power transmission belt 
coupled with an external controller, battery, and wristwatch monitor. One patient 
had early pump thrombosis and a perioperative stroke with a major residual deficit. 
The second patient reached full ambulation, including swimming, within the first 
week of surgery, was discharged from the hospital, and successfully transplanted 
thereafter (6).  
 
 
Figure 1. A. Chest X-ray depicting implantable components topography, B. 
Implantable components C. External components. Reproduced from Pya et al. (6), 
with permission 
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Candidate Selection 
Most programs do not have a rigid upper age limit for LVAD candidates. 
Nevertheless, it is important to remember that elderly patients are at a survival 
disadvantage. A majority (84.5%) of younger patients (< 55 years old) are 
discharged to home, but only 46.8% of adults over 75 years of age were 
discharged home following implantation (p < 0.001) (7). Post-implantation survival 
was 69.6%, 46.2%, and 31.7% at 1-, 3-, and 5-years in patients older than 75 
years of age, respectively, which is starkly different than the respective survival 
rates (87.7%, 70.3%, and 53.7%) of patients less than 55 years of age (p < 0.001) 
(7). 
Also, elderly patients with LVADs had a higher incidence of GIB but lower rates of 
device thrombosis (adjusted hazard ratio [HR] for GIB: 2.52; 95% CI, 2.24-2.84) 
compared to those younger than 55 years of age (7). On the other hand, the 
hazard ratios of pump thrombosis were lower in the oldest cohort (adjusted HR, 
0.40; 95% CI, 0.31-0.52), which might justify a lower intensity of anticoagulation in 
this population (7).   
Pulmonary vascular resistance (PVR), calculated as a transpulmonary gradient 
(mean pulmonary artery pressure minus pulmonary capillary wedge pressure) 
divided by cardiac output, is routinely calculated during transplant/LVAD 
evaluation. According to Uriel et al. (8), the transpulmonary gradient, which is 
directly measured, rather than calculated, and therefore is less susceptible to 
error, is more valid for prognosis. However, the transpulmonary gradient scores 
did not predict survival while on LVAD support. In patients who were successfully 
transplanted after being bridged with LVAD, a transpulmonary gradient of >10 mm 
Hg, which was the median on pre-LVAD measurement, was associated with 
reduced one-year survival rates (80% vs. 91%; p = 0 .016). To the contrary, below 
or above the median PVR pre-LVAD did not impact survival rates (8). 
The pulmonary function study, which is another routine test during candidate 
selection, does not appear useful. There was no association between baseline 
pulmonary function tests and survival time post-LVAD or the incidence of 
perioperative right ventricular (RV) failure (9). 
Another study looked into candidates who were referred for LVAD evaluation and 
were rejected by the selection committee at a single center (10). Their yearly 
acceptance rate ranged between 57% and 75%. Reasons for rejection included: 
patient being too sick (34%); psychosocial concerns (25%); patient declined 
(16%); decision was deferred for medical optimization (15%); or patient being too 
healthy (10%). Psychosocial concerns included poor social support (71%), a 
history of non-compliance (16%), and a history of drug abuse (13%) (10). The one-
year survival of rejected patients was 42% in those who were too sick, 64% in 
those with psychosocial concerns, 68% in patients who declined, 86% in those 
deferred for medical optimization, and 100% in those too healthy (P < 0.01). A 
subset analysis of 40 patients who were rejected because of poor social support 
had a 46% one-year mortality (10). These data may be a sign that increasing 
flexibility in patient acceptance by the programs may be beneficial for the patients. 
Denial of a life-saving device because of circumstances that the patient cannot 
control sentences them to a 50% chance of death in the next year. While we all 
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want our patients with LVADs to be safe, the rate of life-threatening situations on 
LVAD support is certainly less than 50% a year.  
Management of Patients on LVAD Support 
Multidisciplinary team 
Last year, the Montefiore LVAD program implemented a number of changes in 
their protocols that were associated with a significant increase in one-year survival 
(74.6% to 100% [p= 0.0002]) (11). Further, one-year survival free of serious 
adverse events (reoperation to replacement of the device or disabling stroke) 
increased from 70.4% to 84.9% (p= 0.059). At the same time, rates for disabling 
stroke, measured as event per patient-year, decreased from 0.15 to 0, (p= 0.019). 
Rates of GIB decreased from 0.87 to 0.51 (p= 0.11) as did driveline infection rates 
(0.24 to 0.10, p= 0.18). The changes included: 
- daily, simultaneous cardiology/cardiac surgery/critical care/pharmacy/coordinator    
  rounds 
- pharmacist-directed anticoagulation 
- speed optimization echocardiogram before discharge 
- comprehensive device thrombosis screening and early intervention 
- use of a BP clinic with pulsatility-adjusted goals 
- early follow-up after discharge  
- individual long-term coordinator/cardiologist assignment 
- systematic training and credentialing of ancillary in-hospital providers (11). 
Emergencies on LVAD 
The Heart Failure Society of America, the Society for Academic Emergency 
Medicine, and the International Society for Heart and Lung Transplantation 
published an expert consensus document that included a decision matrix to guide 
the management of emergencies in LVAD patients (12).   
 
Figure 2. Modified flowchart from Givertz et al. (12). 
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For comparison, we are reproducing our own algorithm published in the VAD 
Journal (13). 
 
Figure 3. Approach to Unresponsive patient with LVAD (13)  
 
Optimization of Blood Pressure   
The discussion regarding optimal BP and BP control in patients with LVADs is 
ongoing. According to a study of INTERMACS data, patients with chronically low 
mean arterial pressure (MAP, ≤ 75 mm Hg), Doppler (≤ 80 mm Hg), and systolic 
BP (< 90 mm Hg) had a 35%-42% higher adjusted HR of death as compared to 
patients with a normal or high BP (p ≤ 0.0001) (14). At the same time, patients with 
higher than normal BP (MAP > 100 mm Hg, Doppler ≥ 105 mm Hg, and systolic 
BP ≥ 120 mm Hg) had a 17%-20% higher adjusted HR of death than those with 
normal pressures (p < 0.05). In patients with axial-flow LVADs, elevated systolic 
BP but not MAP correlated with an increased incidence of stroke (HR, 1.07; 95% 
CI, 1.03−1.11) per 10 mm Hg increase in systolic BP (P= 0.001). Of note, patients 
in the low MAP and Doppler groups were also more likely to have increased 
incident RV failure (p < 0.001). Authors suggest that overaggressive 
pharmaceutical management of BP in patients with LVADs should be avoided 
because excessive afterload reduction may be, in fact, harmful. In general, MAP 
between 75 and 90 mm Hg seems to be optimal, while deviations in either 
direction are associated with less favorable outcomes (14). 
When arterial line BP and Doppler opening pressure were measured 
simultaneously, Doppler opening pressure had a good correlation with invasive 
MAP (r= 0.742, P < 0.0001) and more closely approximated MAP than systolic BP. 
Therefore, Doppler opening pressure might be an acceptable, standard non-
invasive method of BP measurement (15).   
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Optimization of Hemodynamics 
The importance of achievement and maintenance of optimal hemodynamics in 
patients with LVAD has gained more and more recognition. In last year’s review, 
we cited a paper by Imamura et al. that demonstrated a decreased rate of all 
adverse events in LVAD patients if hemodynamics were normal or near normal 
(16). There are two ways to improve hemodynamics in LVADs: 1) adjust pump 
parameters and/or 2) maximize the performance of the native left ventricle (LV) by 
using guideline-recommended heart failure (HF) drugs. The following details the 
new developments of 2019: 
1) Ramp test 
The same group of authors (Imamura et al) (17) published a 2019 study 
(seemingly with some overlap with the previous paper) where LVAD speed 
was optimized using a ramp test, targeting the following goals:  central 
venous pressure, < 12 mm Hg; pulmonary capillary wedge pressure, < 18 
mm Hg; and cardiac index > 2.2 L/min/m2. The total hospital readmission 
rate was lower in the optimized group compared with the non-optimized 
group (1.15 versus 2.86 events/year, p < 0.001). This result was 
predominantly because of a reduction in the HF readmission rate in the 
optimized group (0.08 versus 0.71 events/year, p= 0.016). Survival was 
similar. In 39% of patients, hemodynamics could not be optimized. This 
was most frequently due to a lower pulmonary artery pulsatility index, 
inability to decrease central venous pressure to normal levels, or because 
of coexisting atrial fibrillation (17).   
Curiously, a novel method of estimation of central venous pressure in 
patients with LVADs and biventricular pacemakers was suggested by 
Imamura et al. (18). The empiric formula below had a significant correlation 
(r = 0.795) and good agreement with the measured central venous 
pressure (mean difference -0.14 ± 1.77 mm Hg). Applying the above 
equation to the validation cohort showed a strong association with 
measured central venous pressure (r = 0.705). 
Central venous pressure = 47.90-(0.086 × right atrial lead impedance) + 
(0.013 × RV lead impedance)-(0.020 × LV lead impedance) (18).  
2) Medical management 
There is a growing recognition of the need to continue guideline-
recommended HF medications after LVAD implantation. Last year, we 
referenced the lower mortality found when patients maintained HF 
medications (19). In 2019, Mccolough et al. (20) showed similar results 
from a new analysis of the INTERMACS database. The overall utilization of 
this therapy was low. At the 6-months post-LVAD implantation, only 16.2% 
of patients were receiving triple therapy, and only 22.6% were receiving an 
angiotensin converting enzyme inhibitor or angiotensin receptor blocker 
(ACEI/ARBs) and a beta-blocker. The unadjusted 4-year survival estimate 
for patients receiving neurohormonal blockers was 56.0% (95% CI, 54.5%-
57.5%), compared with 43.9% (95% CI, 40.5%-47.7%) for patients not 
receiving them (p < 0.001). Also, patients receiving triple therapy with an 
ACEI/ARB, a beta-blocker, and an aldosterone antagonist at 6-months 
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post-LVAD had the longest survival estimate at four years (66.4%; 95% CI, 
63.1%-70.0%). In an adjusted model, however, survival benefit became 
insignificant. The six-minute walk results were also better in the patient 
cohort on HF medications (20). Another study summarized experiences 
from two centers, and their data showed treatment with ACEI/ARBs was an 
independent factor associated with decreased post-LVAD mortality (21).  
2019 also yielded the first report on the tolerability of sacibutril/valsartan in 
patients with LVADs (22). Out of five patients who started taking this 
medication, three had to discontinue this drug due to hypotension-related 
symptoms (22). 
The favorable effect of LVAD on diabetes has been previously reported 
(23-26); however, for the first time last year, we demonstrated a significant 
reduction in fasting blood glucose after LVAD implantation in both diabetic 
and non-diabetic patients (27). In diabetic patients, there was an overall 
reduction in insulin requirements from an average of 29.2 units per day 
before the LVAD to 16.2 units per day before discharge (p= 0.038) (27). In 
addition, the beneficial effect of an LVAD on other metabolic and hormonal 
variables, such as free and total testosterone, thyroid-stimulating hormone, 
and free T4, was shown by Nguen et al. (28).  Before implantation, 75% of 
patients had insulin resistance, 86% of men and 39% of women had low 
free testosterone, and 44% of patients had abnormal thyroid function. 
There was a significant improvement in all of the measures following 
implantation (p < 0.001 for all). Patients with a normal hemoglobin A1C (< 
5.7%) following implantation also had a higher 1-year survival free of HF 
readmissions (78% versus 23%; P < 0.001). Patients with metabolic 
parameters within normal range following LVAD implantation also had 
higher 1-year survival free of HF readmissions (92% versus 54%; p= 0.04). 
Radiation Therapy in LVAD 
A case of radiation therapy for lung cancer in a patient with a HM3 device was 
reported in 2019, and radiotherapy appeared to be safe in terms of continued 
LVAD function (29). In the past, there were eight case reports on radiation therapy 
with LVADs (HMII and Heartware) in the radiation field (29). The maximal reported 
doses received directly to a VAD was 4900 cGy with a mean of 1922 cGy for a 
gastroesophageal junction tumor. None of the patients experienced LVAD-related 
complications or pump malfunction (29). 
Recovery Evaluation 
Last year, we published the flow chart for recovery evaluation (30), based on the 
work of the Berlin group (31). This year, Nir Uriel’s group at the University of 
Chicago shared their reverse ramp test protocols (Table 1), which assess 
myocardial recovery (32). The group routinely performs such tests at the 6–12 
months post-LVAD implantation timepoints in patients <50 years of age with a 
short duration of HF (<2–5 years). In the reverse ramp test, device speed is 
reduced to minimal settings, which requires anticoagulation with an international 
normalized ratio (INR) of 2–3.5 to limit the risk of device thrombosis. 
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Interestingly, with progressive decreases in LVAD speed, and hence reloading of 
the LV, the left ventricular ejection fraction improved from baseline post-VAD 
(30.67% ±10.15%) to the last step (46.05% ±14.19%). The pulmonary capillary 
wedge pressure also increased from 8.86 ±3.08 mm Hg to 12.50 ±2.04 mm Hg; 
the mean pulmonary artery pressure remained stable; and the central venous 
pressure increased minimally from 7.14 ±2.91 mm Hg to 8.17 ±3.34 mm Hg. 
Cardiac output decreased slightly during the test from 5.92 ±0.55 L/min to 5.44 
±0.51 L/min. As a result, three out of seven patients were suitable for pump 
decommissioning (32).  
 












HeartWare 2,400 199 3 1,800 
HMII 8,000 400 3 6,000 
HM3 5,000 100 3 4,000 
Echo parameters 
recorded for each step 
left ventricular end-diastolic diameter, left ventricular 
end-systolic diameter, aortic valve opening, degree 
of aortic insufficiency, and mitral regurgitation 
Hemodynamic 
parameters recorded for 
each step 
central venous pressure; systolic, diastolic and 
mean pulmonary artery pressure; pulmonary 
capillary wedge pressure; pulmonary artery 
saturation; cardiac output; cardiac index  
Pump parameters 
recorded for each step 
HM II and HM3: speed, pulsatility index, flow, power 
Heartware: speed, upper flow, lower flow, average 
flow, power 
Rpms – revolutions per minute; HMII – HeartMate II; HM3- HeartMate 3 
 
LVAD and Valves 
Mitral Valve 
MitraClip (Abbott) is becoming an established procedure in many programs. So 
far, LVADs have been implanted in patients with MitraClips, and reports indicate 
the procedure is safe. Current data indicates that there is no need for additional 
procedures on the mitral valve (33). 
Aortic Valve 
New data were published about the importance of aortic regurgitation in LVADs. If 
the regurgitant fraction exceeds 30%, one-year survival free of major adverse 
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events (bleeding, stroke, pump thrombosis) was 44% compared to 67% in patients 
without significant aortic insufficiency (P = 0.018) (34).   
Transcatheter aortic valve replacement was again found to be a feasible and safe 
procedure in LVAD patients, resulting in complete resolution of aortic regurgitation 
(35). 
Tricuspid valve 
The topic of concomitant procedures on the tricuspid valve during LVAD 
implantation remains controversial. By some data, such procedures did not 
improve patient outcomes but reduced the incidence of 30-day readmission (36). 
Other data indicates the concomitant procedure increased cardiac output with 
unknown clinical consequences (37).   
Arrhythmia 
There was an important analysis of the site of origin of ventricular tachycardia in 
LVADs (38). Scar-related re-entry was the predominant mechanism (90.3%), and 
cannula-related ventricular tachycardia was found only in 19.3% cases. In cases of 
electrical storm, ablation was successful in 90% of the cases (38). 
Ventricular arrhythmia continues to be an indicator of increased mortality after 
LVAD. When ventricular arrhythmia occurs in the first month after LVAD 
implantation, especially if presenting as electrical storm, it was associated with a 7-
fold increase of 30-day mortality (39). Fortunately, after the patients are 
discharged alive, early ventricular arrhythmias have no further bearing on the 
prognosis (39). Congruently, in another study, 32.8% of patients presenting with 
electrical storm died within the next two weeks (40). Electrical storm was defined 
as at least three separate episodes of sustained ventricular tachycardia or 
appropriate implantable cardioverter defibrillator (ICD) shocks within a 24-hour 
period (40). 
Two new observational studies from Cleveland Clinic analyzed the presence of 
ICDs (41) and atrial fibrillation/flutter (42) in LVAD patients. Neither was associated 
with different outcomes than in patients without ICDs or atrial tachyarrhythmia, 
respectively. There do not seem to be strong data in favor of implanting ICDs in 
patients who did not have them before the LVAD (41). Also, there is no evidence 
that controlling the rate in atrial arrhythmias improves outcomes. Atrial fibrillation or 
flutter was not associated with increased mortality, thromboembolism, or bleeding 
(38, 42).  
Also, this year, a scientific statement from the American Heart Association was 
published. It provides detailed recommendations on the management of 
arrhythmias in LVAD recipients (43). 
Complications of the VADs 
LVAD Outflow graft obstruction 
Last year, we dedicated a significant portion of the review to outflow graft 
obstruction research. The following summarizes the findings: 
• Surgical Technique:  Gore-tex around the outflow tract 
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• Timing:  Months to years after the implantation 
• Symptoms:  HF, low flows, with or without low flow alarm, and decreased 
pulsatility index 
• Hemolysis:  No 
• Diagnosis:  Computer tomography angiography (CTA) 
• Treatment:  Stenting 
• Prevention:  Discontinuation of wrapping the outflow tract with the Gore-tex 
(30) 
However, despite several published cases and case series, the incidence of this 
complication remains unknown. In a 2019 retrospective study, all patients with 
CTAs done for any reason were examined for the outflow graft narrowing, defined 
as the internal luminal diameter of the outflow graft < 10 mm (44). 14% of patients 
had evidence of outflow graft lumen narrowing, all in HeartMate® devices and all 
within the portion covered by the bend relief, with biodebris between the bend 
relief and the outflow graft. Time from implant to scan (p < 0.001), nonischemic 
cardiomyopathy (p= 0.017), and patient age at the device implant (p= 0.003) were 
significantly associated with LVAD outflow graft narrowing (44).   
Because patients had a CTA for clinical reasons, one of which is suspected pump 
thrombosis or low flow state, this incidence rate may be higher than in all LVAD 
recipients. Curiously, in this series, there were no cases of outflow graft 
obstruction in HeartWare® devices. Authors postulate that the HeartWare design 
allows greater accumulation of debris without lumen narrowing (44). However, last 
year, we summarized published case reports, which included four cases of outflow 
graft obstruction in HeartWare pumps. This year, Nathan et al. published the 
largest case series of 12 outflow graft obstruction cases (45). 25% (3/12) cases 
occurred with the HeartWare device. Another series of note included five patients 
(46); four of these cases had HeartWare devices.  
Stroke 
Since the Evaluate the HeartWare Ventricular Assist System for Destination 
Therapy of Advanced Heart Failure (ENDURANCE) Trial was published in 2017 
(47),  the increased rate of strokes on HeartWare devices as compared to HMII 
support (29.7% vs. 12.1%, P<0.001) has been heeded by many as a word of 
caution when it comes to the choice of pump.  
However, in 2019, Li et al. identified and analyzed neurologic events in key clinical 
trials and registries (48). He compared the HMII, HM3, and HeartWare devices 
and found the neurologic event rates were comparable when standardized as 
events per patient-year (HM3 = 0.17-0.21; HMII = 0.19-0.26; HeartWare = 0.16-
0.28) (48). It appears that patient selection was key to the earlier reported 
discrepancies, and no pump outperforms others in terms of stroke rate. 
Gastrointestinal Bleeding 
Gastrointestinal bleeding on LVAD support is a frustrating complication requiring 
extensive work up in search of a bleeding cause and location. Axelrad et al. 
proposed an algorithm for LVAD-associated GIB (49). Adherence to this algorithm 
was associated with a 68% increase in the diagnostic yield and a 113% increase in 
the therapeutic yield of endoscopy. Also, it decreased the length of stay by four 
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days and reduced the number of procedures per patient by 27% and cost by 18% 
(Figure 4). 
 
Figure 4. Algorithm for diagnostic workup for gastrointestinal bleeding. 
Modified from Axelrod et al. (49) 
 
In terms of treatment, there is growing evidence that the medical management of 
patients on LVAD may produce benefits seemingly unrelated to HF, BP control, or 
LV reverse remodeling. In the retrospective cohort from of the University of 
Minnesota, ACEI/ARB use was associated with a reduction in the incidence rate of 
GIB (unadjusted 78% reduction; 95% CI, 0.10-0.48; p < 0.00001; adjusted 67% 
reduction; 95% CI, 0.15-0.71; p= 0.005) (50). This protective effect is similar to the 
observations of Houston et al. (51).  
Another new study also showed that patients who received an ACEI/ARBs within 
30 days after LVAD implantation had a 57% reduction in the risk of major GIB, 
defined as bleeding requiring ≥ 2 units of packed red blood cells or resulting in 
death (HR, 0.43; 95% CI, 0.19-0.97; p= 0.042) and a 63% reduction in the risk of 
arterio-venous malformations-related GIB. Moreover, when the mean daily 
lisinopril-equivalent ACEI /ARB dose was >5 mg, the risk of major GIB decreased 
in a dose-threshold manner (HR, 0.28; 95% CI, 0.09-0.85; p= 0.025). Prevention of 
the development of arterio-venous malformations was proposed as a potential 
mechanism (52). 
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Other medications may also play a role in GIB. A retrospective review found that 
selective serotonin reuptake inhibitors, commonly prescribed for depression, are 
associated with GIB post-LVAD (53). Patients receiving these medications 
developed GIB due to arterio-venous malformations at the rate of 24.8% versus 
14.7% in patients not receiving them (53). 
Thalidomide therapy was again found to be effective for GIB in LVAD patients, 
reducing the risk of rebleeding (HR, 0.23; p= 0.022). The median number of GI 
bleeds per year was reduced from 4.6 to 0.4 (p= 0.0008), and the packed red 
blood cell requirement was lower (36.1 vs. 0.9 units per year, p= 0.004) in those 
on thalidomide therapy. The adverse event rate with thalidomide was high at 59%, 
with symptoms resolution in most following dose reduction without increased 
bleeding (54).   
RV failure 
An interesting case was reported from the University of Toronto, where a patient 
with an LVAD and RV failure progressed to asystole with a complete cardiac 
standstill (55). Her hemodynamics were maintained by LVAD with no contribution 
from the RV until she received a heart transplant (55). In an equally interesting 
commentary, Imamura (56) compared this case with the one a patient on LVAD 
support and sustained ventricular fibrillation. He suggested that in such cases of 
"Fontan-like circulation," with LVAD performing the function of the LV and RV 
being completely passive, circulation can be maintained with the following 
hemodynamic parameters: central venous pressure of 15–20 mm Hg, pulmonary 
capillary wedge pressure of 10–15 mm Hg, and low PVR around 2.0 Wood units 
(56). An elevated central venous pressure was needed because a relatively high-
volume status is required to maintain the preload of LV without any help from the 
RV. 
What is new in VA ECMO World? 
The 2019 American Heart Association Focused Update on Advanced 
Cardiovascular Life Support confirmed that there is insufficient evidence to 
recommend the routine use of extracorporeal cardiopulmonary resuscitation 
(ECPR) for patients with cardiac arrest (57). ECPR may be considered for selected 
patients as rescue therapy when conventional CPR efforts are failing in settings in 
which it can be expeditiously implemented and supported by skilled providers 
(Class 2b; Level of Evidence C-LD) (57). 
Like in continuous-flow LVADs, blood management on VA ECMO remains a topic 
of discussion. While lower pressure can lead to end-organ hypoperfusion, a higher 
pressure may compete with ECMO flow and cardiac output. In a retrospective 
study of 124 patients, the average MAP was significantly higher in patients who 
survived to discharge (82 ± 5.6 vs. 78 ± 5.5 mm Hg, p= 0.0003) (58). Survival was 
best with a MAP higher than 90 mm Hg (71%) and worst with a MAP less than 
70 mm Hg, where no patient survived. MAP was an independent predictor of 
survival to discharge by multivariate analysis (odds ratio 1.17, p= 0.013). Also, 
patients with a higher MAP had a lower incidence of kidney injury (p= 0.007) (58).  
For the first time, the excessive fluid accumulation while on VA ECMO support was 
directly linked to increased short-term mortality (59). The net fluid balance was 
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higher in non-survivors than in survivors on Day 1 ECMO support (47.3 [18.1-71.9] 
vs 19.3 [1.5-36.2] mL/kg, p  <  0.0001) and Day 2 (30.6 [14.8-71.0] vs 10.1 [-9.8-
34.7] mL/kg, p = 0.025), as was the cumulative fluid-balance over the first 5 days 
(107.3 [40.5-146.2] vs 53.0 [7.5-74.3] mL/kg, p =  0.04). Moreover, a threshold of 
38.8  mL/kg predicted mortality with a sensitivity of 60% and specificity of 83% 
(59). 
Another topic of growing interest is LV venting. A systematic literature review 
analyzed mortality on VA ECMO based on the timing of LV venting (60). Overall, 
LV venting significantly improved weaning from VA ECMO (odds ratio, 0.62; 95% 
CI, 0.47-0.83; p= 0.001) and reduced 30-day mortality (risk ratio 0.86; 95% CI, 
0.77-0.96; p= 0.008) but not in-hospital or 6-month mortality. Importantly, early (< 
12 hours) but not late (≥ 12 hours) LV venting reduced short-term mortality 
signficantly. In terms of the method of venting, the majority of patients had an intra-
aortic balloon pump (43%) (60). 
Another analysis of published literature found that the intra-aortic balloon pump 
was chosen as a venting device in 91.7% of patients on VA ECMO who had LV 
venting (61). Mortality was lower in patients with (54%) versus without (65%) LV 
unloading while on VA-ECMO (risk ratio, 0.79; 95% CI, 0.72-0.87; p < 0.00001) 
(61). 
Along the same lines, Vallabhassula et al. (62) reviewed the literature to compare 
early mortality in patients with cardiogenic shock treated with ECMO plus Impella 
(Abiomed) (ECPELLA) to VA ECMO alone. They found that the use of ECPELLA 
was associated with higher weaning from VA ECMO and bridging to permanent 
LVAD or cardiac transplant. Also, the studies that accounted for differences in 
baseline characteristics between treatment groups reported lower 30-day mortality 
with ECPELLA versus VA ECMO (62).   
LV venting with a transseptal 24-Fr multiple-side-hole cannula with a length of > 55 
cm that could effectively decompress both the right and left heart was reported by 
Na et al. (63). If the device was used prophylactically, before LV distension, the 
30-day mortality rate was 5.6%, but if the cannula was inserted for treatment of LV 
distension after it occurred, the mortality was 34.4% (P= 0.036). The rate of 
successful weaning from ECMO and the duration of ECMO support were not 
significantly different between the groups. However, the rate of bridging to cardiac 
replacement therapy, such as heart transplantation or LVAD, was significantly 
higher in the prophylactic group (66.7%) than in the therapeutic group (37.5%) (P= 
0.048) (63). 
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